famotidine has been researched along with Gastric Ulcer in 171 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed two 24-week double-blind trials (REDUCE-1 and -2 (Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efficacy and Safety Studies)) to assess whether double-dose famotidine given in a single-tablet combination with ibuprofen (HZT-501) significantly reduces gastric and duodenal ulcers as compared with ibuprofen." | 9.16 | Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. ( Bello, AE; Grahn, AY; Kivitz, AJ; Laine, L; Schiff, MH; Taha, AS, 2012) |
| " This study aimed to compare the effects of omeprazole and famotidine on ulcer healing and fibroblast growth factor-2 levels in gastric ulcers induced by endoscopic mucosal resection." | 9.10 | Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans. ( Aoyagi, K; Esaki, M; Fujishima, M; Kuwano, Y; Matsumoto, T; Shimizu, M, 2002) |
| "We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer." | 9.08 | Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. ( Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S, 1995) |
| "We studied the action on acid secretion of lansoprazole compared with famotidine by 24-h intragastric pH monitoring, evaluated its clinical effects prospectively, and assessed the importance of acid inhibition in gastric ulcer patients." | 9.08 | Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. ( Ashida, K; Katsu, K; Miyoshi, H; Sakaguchi, M; Umegaki, E, 1995) |
| "To compare the efficacy of lansoprazole and famotidine in the treatment of gastric ulcer, 24 patients with gastric ulcer were treated for 8 weeks." | 9.08 | Comparison of lansoprazole and famotidine for gastric ulcer by endoscopic ultrasonography: a preliminary trial. ( Motoo, Y; Okai, T; Sawabu, N; Songür, Y; Watanabe, H, 1995) |
| "We studied the efficacy of two doses of famotidine (20 mg and 40 mg, each given orally twice daily), as compared with placebo, in preventing peptic ulcers in 285 patients without peptic ulcers who were receiving long-term NSAID therapy for rheumatoid arthritis (82 percent) or osteoarthritis (18 percent)." | 9.08 | Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. ( Cottrell, J; Hawkey, CJ; Hudson, N; Mann, SG; Russell, RI; Simon, TJ; Sturrock, RD; Swannell, AJ; Taha, AS; Trye, PN, 1996) |
| "The effects of single morning and single bedtime doses of famotidine on intragastric acidity were studied by 24-h intragastric pH monitoring in 16 patients with gastric ulcer." | 9.07 | Comparison of the effects of single morning and single bedtime doses of famotidine on intragastric acidity in patients with gastric ulcer. ( Arita, M; Hosiko, K; Matsui, T; Motomura, A; Okada, M; Yao, T, 1994) |
| "A randomized controlled study comparing once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating gastric ulcers was carried out in 179 Japanese patients." | 9.07 | A comparative study of once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating gastric ulcers. ( Arita, M; Iida, M; Koga, T; Okabe, N; Okada, M; Okada, Y; Sakurai, T; Yao, T, 1992) |
| "We conducted a double blind random study on 79 patients with gastric ulcer: 39 received sucralfate, 1 g 4 times a day (Group 1) and 40 received a single evening dose of famotidine, 40 mg (Group 2)." | 9.07 | [Treatment of gastric ulcer with sucralfate and famotidine]. ( Hoffenberg, P; Klinger, J; Maggiolo, P; Ossa, P; Palma, J; Reyes, V, 1991) |
| "A multicentre, double-blind, randomized, placebo-controlled trial was undertaken to investigate the therapeutic efficacy of a nocturnal dose of famotidine 20 mg to reduce the 1 year relapse rate of recently healed gastric ulcers." | 9.07 | Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcer. ( Berlin, RG; Cook, TJ; Root, JK, 1991) |
| "A multicenter, double-blind, randomized controlled trial comparing the efficacy and safety of famotidine with ranitidine in the treatment of acute, benign gastric ulcer disease was coupled with a community-based gastric ulcer disease registry." | 9.06 | Randomized, double-blind comparison of famotidine with ranitidine in treatment of acute, benign gastric ulcer disease. Community-based study coupled with a patient registry. ( Brazer, SR; Brice, RS; Garbutt, JT; Harrell, FE; Liss, CL; Pancotto, FS; Pryor, DB; Root, JK; Tyor, MP; Wildermann, NM, 1989) |
| "The worldwide experience with famotidine in the management of benign gastric ulcers is reviewed." | 9.06 | Efficacy and safety of famotidine in the management of benign gastric ulcers. ( Lyon, DT, 1986) |
| "Three hundred thirty-six patients with endoscopically diagnosed benign gastric ulcers, randomly allocated to treatment with 40 mg famotidine at night or placebo, were evaluated in a double-blind multicenter trial conducted in 14 countries worldwide." | 9.06 | Famotidine once-a-day in the therapy of acute, benign gastric ulcer: a worldwide experience. ( Dammann, HG; Müller, P; Simon, B, 1987) |
| "An 8-week, double-blind, randomized, placebo-controlled, multinational (n = 14), multicenter (n = 44) trial was conducted to determine whether famotidine speeds healing and relief of symptoms in patients with benign gastric ulcer." | 9.06 | Famotidine: proven once-a-day treatment for gastric ulcer. ( Dammann, HG; Hentschel, E; Muller, P; Simon, B; Walter, TA, 1987) |
| "The aim of the present investigation was to study the efficacy and safety of famotidine (MK-208), a new, potent, histamine H2 receptor antagonist, in promoting the healing of active gastric ulcer when compared to placebo." | 9.05 | Famotidine (MK-208) in the treatment of gastric ulcer. Results of a multicenter double-blind controlled study. ( Barbara, L; Bianchi Porro, G; Blasi, A; Carratelli, L; Cheli, R; Corinaldesi, R; Lazzaroni, M; Mangiameli, A; Paoluzi, P; Torsoli, A, 1985) |
| "The new H2 receptor antagonist, famotidine, has been tested in open and double-blind studies in over 2,000 acute duodenal or gastric ulcer patients as well as in the maintenance of chronic duodenal ulcer patients." | 9.05 | Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience. ( Bianchi Porro, G, 1985) |
| "We conducted an 8-week, double-blind, randomized, placebo-controlled multicenter trial (Austria and Germany) to determine whether famotidine would speed healing or relief of symptoms in patients with benign gastric ulcer." | 9.05 | Famotidine: nocturnal administration for gastric ulcer healing. Results of multicenter trials in Austria and Germany. ( Dammann, HG; Hentschel, E; Müller, P; Simon, B; Walter, TA, 1985) |
| "Although anti-inflammatory doses of ibuprofen are very effective in treating the signs and symptoms of osteoarthritis (OA), they come with an increased risk for gastrointestinal damage which can limit their use and decrease patient adherence to therapy." | 8.90 | Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. ( Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014) |
| " The present work aimed to annotate the secondary metabolites from a butanol fraction of apple leaves (BLE), evaluate the gastro-protective and healing effects of this fraction against indomethacin-induced gastric ulcers in rats and to identify its mechanism of action." | 8.31 | Apple (Malus domestica Borkh) leaves attenuate indomethacin-induced gastric ulcer in rats. ( Abdelfattah, MAO; Abdo, W; Drissi, B; El-Shazly, AM; Mahmoud, MF; Nabil, M; Sobeh, M, 2023) |
| "Single-tablet ibuprofen/famotidine is approved by the US Food and Drug Administration for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal (GI) ulcers in patients taking ibuprofen for those indications." | 7.79 | Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis. ( Holt, RJ; Johnson, KE; Kent, JD; Kuan, R; Malone, D; Peura, DA, 2013) |
| "To assess the synergistic action of famotidine (FMD) and chlorpheniramine (CPA) on acetic acid-induced chronic gastric ulcer in rats." | 7.73 | Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats. ( Chen, C; Qin, Z, 2005) |
| "To describe a patient who developed delirium when switched from cimetidine to famotidine." | 7.71 | Delirium following a switch from cimetidine to famotidine. ( Chen, CH; Ho, CS; Kao, CR; Sheu, JJ; Yuan, RY, 2001) |
| "Effect of lafutidine ((+/-)-2-(furfurylsulfinyl)-N-[4-[4-(piperidinomethyl)-2-pyr idyl] oxy-(Z)-2-butenyl] acetamide, FRG-8813), a novel antiulcer agent, on the healing and relapse in acetic acid-induced gastric ulcer in rats was investigated." | 7.70 | [Effect of lafutidine, a novel antiulcer agent, on healing and relapse of acetic acid-induced gastric ulcer in rats]. ( Aoyama, M; Arai, Y; Ohnishi, H; Onodera, S; Shibata, M; Tanaka, M; Yamaura, T, 1998) |
| "The effects of IGN-2098 on the healing process of acetic acid-induced gastric ulcer was investigated in comparison with the other histamine H2-receptor antagonists, famotidine and roxatidine acetate HCl, in rats." | 7.69 | [Therapeutic effect of IGN-2098, a new antiulcer drug (H2-antagonist), in the ulcer diminishing period against acetic acid-induced gastric ulcer in rats]. ( Ikarashi, Y; Misaki, N; Ohba, S; Ohbayashi, S; Uchida, M, 1995) |
| "In order to evaluate the efficacity and tolerance of Famotidine in the treatment of gastric ulcer, in Lebanese patients, we conducted a prospective open study in twenty one patients with benign gastric ulcer." | 7.68 | [Famotidine in the treatment of stomach ulcer]. ( Khoury, K; Nassr, W; Sayegh, R, 1992) |
| " Adverse events (AEs) were collected beginning at the first dose and continued through completion (54 weeks)." | 6.80 | One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| "Irsogladine has previously been shown to accelerate the healing of gastric ulcers after H." | 6.76 | Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. ( Abe, H; Arita, T; Fujioka, T; Kodama, M; Mizukami, K; Murakami, K; Okimoto, T; Shuto, M; Tanahashi, J, 2011) |
| "When healing of gastric ulcers is observed using an electronic endoscope with a magnifying function, five types of regenerated mucosa can be distinguished." | 6.68 | Effects of lansoprazole on mucosal regeneration in patients with gastric ulcers: evaluation using an electronic endoscope with a magnifying function. ( Fukuchi, S; Hashimoto, M; Hoshihara, Y; Iguchi, D; Kimura, T; Sugawara, K; Takemoto, T; Tanaka, T; Yamamoto, T, 1995) |
| "Famotidine was well-tolerated and no serious clinical or laboratory adverse effects were judged to be related to this dosing regimen of famotidine." | 6.66 | Suppression of nocturnal acid secretion with famotidine accelerates gastric ulcer healing. ( Graham, DY; Knuff, TE; Lanza, FL; Levenson, HL; Lyon, DT; McCullough, AJ; Munsell, WP; Perozza, J; Roufail, WM; Sinar, DR, 1989) |
| "Ibuprofen/famotidine was generally well tolerated, with a tolerability profile consistent with those established for the individual agents." | 6.49 | Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. ( Deeks, ED, 2013) |
| "Felodipine is a calcium channel blocker with antioxidant and anti-inflammatory properties." | 5.91 | Effect of felodipine on indomethacin-induced gastric ulcers in rats. ( Akbaş, EM; Akbaş, N; Gülaboğlu, M; Mammadov, R; Süleyman, B; Süleyman, H, 2023) |
| " Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastric ulcers and one duodenal ulcer)." | 5.34 | Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. ( Chan, FKL; Ching, JYL; Chiu, PWY; Lau, JYW; Lau, LHS; Ling, RHY; Tse, YK; Wong, GLH; Wong, VWS, 2020) |
| "Gastric ulcer is a multifaceted process including acid secretion, reactive oxygen species generation, prostaglandin inhibition, and extracellular matrix (ECM) degradation." | 5.34 | Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer. ( Ganguly, K; Kundu, P; Mishra, A; Pradeepkumar Singh, L; Swarnakar, S, 2007) |
| "Omeprazole was more effective than famotidine in keeping gastric pH high and lowering the total gastric acid output." | 5.32 | Omeprazole is more effective than famotidine for preventing acute gastritis in rats. ( Akturk, Z; Ekinci, H; Muftuoglu, T; Peker, O; Topaloglu, U; Unalmiser, S, 2004) |
| "Dimethylglycine did not produce any significant change in acid secretion, unlike famotidine." | 5.31 | Effect of dimethylglycine on gastric ulcers in rats. ( Hariganesh, K; Prathiba, J, 2000) |
| "In the pivotal efficacy and safety trials, discontinuation rates due to any cause and dyspepsia were significantly lower for the ibuprofen/famotidine combination versus ibuprofen alone." | 5.20 | One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| "We performed two 24-week double-blind trials (REDUCE-1 and -2 (Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efficacy and Safety Studies)) to assess whether double-dose famotidine given in a single-tablet combination with ibuprofen (HZT-501) significantly reduces gastric and duodenal ulcers as compared with ibuprofen." | 5.16 | Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. ( Bello, AE; Grahn, AY; Kivitz, AJ; Laine, L; Schiff, MH; Taha, AS, 2012) |
| "A total of 158 patients (155 early gastric cancers and three adenomas) were randomly assigned to the PPI group (omeprazole 20 mg/day) or H(2) RA group (famotidine 40 mg/day) in a prospective randomized controlled trial." | 5.16 | Prospective randomized controlled trial to compare the effects of omeprazole and famotidine in preventing delayed bleeding and promoting ulcer healing after endoscopic submucosal dissection. ( Fukui, H; Hori, K; Kim, Y; Kondo, T; Matsumoto, T; Miwa, H; Morita, T; Okugawa, T; Oshima, T; Sakurai, J; Tanaka, J; Tomita, T; Toyoshima, F; Watari, J; Yamasaki, T, 2012) |
| " This study aimed to compare the effects of omeprazole and famotidine on ulcer healing and fibroblast growth factor-2 levels in gastric ulcers induced by endoscopic mucosal resection." | 5.10 | Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans. ( Aoyagi, K; Esaki, M; Fujishima, M; Kuwano, Y; Matsumoto, T; Shimizu, M, 2002) |
| "To investigate effects of histamine H2-receptor antagonists (cimetidine, famotidine) on proliferative activity of gastric mucosa of patients with acute gastric ulcer." | 5.09 | [The effect of histamine H2 receptor blockers on reparative processes in the gastric mucosa of patients with gastric peptic ulcer]. ( Alekseenko, SA; Timoshin, SS, 1999) |
| " pylori infection and duodenal ulcer, gastric ulcer or non-ulcer dyspepsia were randomly assigned to a 1 week course of either famotidine 80 mg b." | 5.09 | Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. ( Brandstätter, G; Dragosics, B; Gschwantler, M; Hentschel, E; Hirschl, AM; Klimpfinger, M; Oberhuber, G; Pasching, E; Schütze, K; Weiss, W; Wimmer, M; Wurzer, H, 1999) |
| "We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer." | 5.08 | Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. ( Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S, 1995) |
| "We studied the action on acid secretion of lansoprazole compared with famotidine by 24-h intragastric pH monitoring, evaluated its clinical effects prospectively, and assessed the importance of acid inhibition in gastric ulcer patients." | 5.08 | Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. ( Ashida, K; Katsu, K; Miyoshi, H; Sakaguchi, M; Umegaki, E, 1995) |
| "To compare the efficacy of lansoprazole and famotidine in the treatment of gastric ulcer, 24 patients with gastric ulcer were treated for 8 weeks." | 5.08 | Comparison of lansoprazole and famotidine for gastric ulcer by endoscopic ultrasonography: a preliminary trial. ( Motoo, Y; Okai, T; Sawabu, N; Songür, Y; Watanabe, H, 1995) |
| "We studied the efficacy of two doses of famotidine (20 mg and 40 mg, each given orally twice daily), as compared with placebo, in preventing peptic ulcers in 285 patients without peptic ulcers who were receiving long-term NSAID therapy for rheumatoid arthritis (82 percent) or osteoarthritis (18 percent)." | 5.08 | Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. ( Cottrell, J; Hawkey, CJ; Hudson, N; Mann, SG; Russell, RI; Simon, TJ; Sturrock, RD; Swannell, AJ; Taha, AS; Trye, PN, 1996) |
| "The effects of single morning and single bedtime doses of famotidine on intragastric acidity were studied by 24-h intragastric pH monitoring in 16 patients with gastric ulcer." | 5.07 | Comparison of the effects of single morning and single bedtime doses of famotidine on intragastric acidity in patients with gastric ulcer. ( Arita, M; Hosiko, K; Matsui, T; Motomura, A; Okada, M; Yao, T, 1994) |
| " Double-blind comparative studies with a beta-blocker, famotidine, in gastric ulcer (study 1) and in duodenal ulcer (study 2) were conducted." | 5.07 | [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer]. ( Ogawa, N, 1992) |
| "In a two center open uncontrolled clinical trial, the efficacy of a single evening dose of 40 mg famotidine (Ulcusan) was studied in a total of 37 patients (20 with chronic duodenal ulcers, 9 with recurring and 8 with acute gastric ulcers)." | 5.07 | [Therapy of peptic ulcers with famotidine. Report of experiences with an open clinical study]. ( Dragosics, B; Okulski, G; Weiss, W, 1992) |
| "A randomized controlled study comparing once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating gastric ulcers was carried out in 179 Japanese patients." | 5.07 | A comparative study of once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating gastric ulcers. ( Arita, M; Iida, M; Koga, T; Okabe, N; Okada, M; Okada, Y; Sakurai, T; Yao, T, 1992) |
| "We conducted a double blind random study on 79 patients with gastric ulcer: 39 received sucralfate, 1 g 4 times a day (Group 1) and 40 received a single evening dose of famotidine, 40 mg (Group 2)." | 5.07 | [Treatment of gastric ulcer with sucralfate and famotidine]. ( Hoffenberg, P; Klinger, J; Maggiolo, P; Ossa, P; Palma, J; Reyes, V, 1991) |
| "A multicentre, double-blind, randomized, placebo-controlled trial was undertaken to investigate the therapeutic efficacy of a nocturnal dose of famotidine 20 mg to reduce the 1 year relapse rate of recently healed gastric ulcers." | 5.07 | Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcer. ( Berlin, RG; Cook, TJ; Root, JK, 1991) |
| "In a double-blind randomised trial, 40 patients with active gastric or duodenal ulcer were treated with a single nocturnal dose of famotidine 40 mg or ranitidine 300 mg for 4 to 8 weeks." | 5.06 | Double-blind comparison of the safety and efficacy of famotidine with ranitidine in patients with endoscopically diagnosed peptic ulcer. ( Bowalekar, SK; Jha, RJ; Nanivadekar, SA; Navani, SR; Oke, VG; Patel, HD; Raghu, CN; Sawant, PD; Shroff, CP, 1990) |
| "A multicenter, double-blind, randomized controlled trial comparing the efficacy and safety of famotidine with ranitidine in the treatment of acute, benign gastric ulcer disease was coupled with a community-based gastric ulcer disease registry." | 5.06 | Randomized, double-blind comparison of famotidine with ranitidine in treatment of acute, benign gastric ulcer disease. Community-based study coupled with a patient registry. ( Brazer, SR; Brice, RS; Garbutt, JT; Harrell, FE; Liss, CL; Pancotto, FS; Pryor, DB; Root, JK; Tyor, MP; Wildermann, NM, 1989) |
| "The worldwide experience with famotidine in the management of benign gastric ulcers is reviewed." | 5.06 | Efficacy and safety of famotidine in the management of benign gastric ulcers. ( Lyon, DT, 1986) |
| "Three hundred thirty-six patients with endoscopically diagnosed benign gastric ulcers, randomly allocated to treatment with 40 mg famotidine at night or placebo, were evaluated in a double-blind multicenter trial conducted in 14 countries worldwide." | 5.06 | Famotidine once-a-day in the therapy of acute, benign gastric ulcer: a worldwide experience. ( Dammann, HG; Müller, P; Simon, B, 1987) |
| "An 8-week, double-blind, randomized, placebo-controlled, multinational (n = 14), multicenter (n = 44) trial was conducted to determine whether famotidine speeds healing and relief of symptoms in patients with benign gastric ulcer." | 5.06 | Famotidine: proven once-a-day treatment for gastric ulcer. ( Dammann, HG; Hentschel, E; Muller, P; Simon, B; Walter, TA, 1987) |
| "An 8 week, double-blind randomized, placebo-controlled multicenter trial was conducted in Austria, Germany and Italy to determine whether famotidine would speed healing and relief of symptoms in patients with benign gastric ulcer." | 5.05 | [Accelerated healing of ulcus ventriculi by a single evening dose of famotidine. Results of an Austrian-German-Italian multicenter study]. ( Barbara, L; Bianchi-Porro, G; Cheli, R; Dammann, HG; Hentschel, E; Müller, P; Paoluzzi, P; Simon, B; Walter, TA, 1985) |
| "The aim of the present investigation was to study the efficacy and safety of famotidine (MK-208), a new, potent, histamine H2 receptor antagonist, in promoting the healing of active gastric ulcer when compared to placebo." | 5.05 | Famotidine (MK-208) in the treatment of gastric ulcer. Results of a multicenter double-blind controlled study. ( Barbara, L; Bianchi Porro, G; Blasi, A; Carratelli, L; Cheli, R; Corinaldesi, R; Lazzaroni, M; Mangiameli, A; Paoluzi, P; Torsoli, A, 1985) |
| "The new H2 receptor antagonist, famotidine, has been tested in open and double-blind studies in over 2,000 acute duodenal or gastric ulcer patients as well as in the maintenance of chronic duodenal ulcer patients." | 5.05 | Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience. ( Bianchi Porro, G, 1985) |
| "We conducted an 8-week, double-blind, randomized, placebo-controlled multicenter trial (Austria and Germany) to determine whether famotidine would speed healing or relief of symptoms in patients with benign gastric ulcer." | 5.05 | Famotidine: nocturnal administration for gastric ulcer healing. Results of multicenter trials in Austria and Germany. ( Dammann, HG; Hentschel, E; Müller, P; Simon, B; Walter, TA, 1985) |
| "Although anti-inflammatory doses of ibuprofen are very effective in treating the signs and symptoms of osteoarthritis (OA), they come with an increased risk for gastrointestinal damage which can limit their use and decrease patient adherence to therapy." | 4.90 | Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. ( Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014) |
| " In clinical trials, PPI and famotidine (40 mg/d) are proven to have the preventive effect to gastric ulceration induced by low-dose aspirin use." | 4.86 | [Mucoprotective drugs and aspirin-induced gastric injury]. ( Sugiyama, T; Yamawaki, H, 2010) |
| " Early indications that acid suppression was effective in the management of NSAID-related peptic ulcers came from studies showing that gastric ulcers could be healed by omeprazole in patients who continued to take NSAIDs." | 4.80 | Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression. ( Armstrong, D; Lad, R, 1999) |
| "The clinical efficacy of famotidine has been clearly shown in the short- and long-term treatment of a number of acid-related diseases such as duodenal and gastric ulcer as well as in the acute management of reflux esophagitis." | 4.78 | Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview. ( Dammann, HG, 1990) |
| " The present work aimed to annotate the secondary metabolites from a butanol fraction of apple leaves (BLE), evaluate the gastro-protective and healing effects of this fraction against indomethacin-induced gastric ulcers in rats and to identify its mechanism of action." | 4.31 | Apple (Malus domestica Borkh) leaves attenuate indomethacin-induced gastric ulcer in rats. ( Abdelfattah, MAO; Abdo, W; Drissi, B; El-Shazly, AM; Mahmoud, MF; Nabil, M; Sobeh, M, 2023) |
| "Famotidine (FM) is considered among the first-line therapy for treatment of gastric ulcers; however, its poor aqueous solubility resulted in low bioavailability and limited therapeutic efficacy." | 3.96 | Soluplus ( Basha, M; Noshi, SH; Salama, A, 2020) |
| "Single-tablet ibuprofen/famotidine is approved by the US Food and Drug Administration for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal (GI) ulcers in patients taking ibuprofen for those indications." | 3.79 | Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis. ( Holt, RJ; Johnson, KE; Kent, JD; Kuan, R; Malone, D; Peura, DA, 2013) |
| "The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers." | 3.77 | A fixed-dose combination ibuprofen and famotidine (Duexis). ( , 2011) |
| "Screening of three potential antiulcer preparations containing ultralow doses of antibodies to endogenous regulators of ulcer formation (gastrin, histamine, and H2 histamine receptors) on the model of acetic acid-induced gastric ulcer in rats revealed pronounced antiulcer effect of ultralow doses of antibodies to histamine." | 3.75 | Antiulcer activity of preparations containing ultralow doses of antibodies in modeled chronic ulcer in rats. ( Borodavkina, MV; Dolgikh, MP; Dugina, YL; Ogorodnikova, TV; Sergeeva, SA; Sorokina, IV; Tolstikova, TG; Zhukova, NA, 2009) |
| "To assess the synergistic action of famotidine (FMD) and chlorpheniramine (CPA) on acetic acid-induced chronic gastric ulcer in rats." | 3.73 | Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats. ( Chen, C; Qin, Z, 2005) |
| "To describe a patient who developed delirium when switched from cimetidine to famotidine." | 3.71 | Delirium following a switch from cimetidine to famotidine. ( Chen, CH; Ho, CS; Kao, CR; Sheu, JJ; Yuan, RY, 2001) |
| "Defunctionalization of capsaicin-sensitive afferent nerves by pretreatment with a neurotoxic dose of capsaicin aggravates gastric ulcers in rats." | 3.71 | Effects of vanilloid receptor agonists and antagonists on gastric antral ulcers in rats. ( Horie, S; Murayama, T; Tsuchiya, S; Uchida, M; Watanabe, K; Yamamoto, H, 2001) |
| "Effect of lafutidine ((+/-)-2-(furfurylsulfinyl)-N-[4-[4-(piperidinomethyl)-2-pyr idyl] oxy-(Z)-2-butenyl] acetamide, FRG-8813), a novel antiulcer agent, on the healing and relapse in acetic acid-induced gastric ulcer in rats was investigated." | 3.70 | [Effect of lafutidine, a novel antiulcer agent, on healing and relapse of acetic acid-induced gastric ulcer in rats]. ( Aoyama, M; Arai, Y; Ohnishi, H; Onodera, S; Shibata, M; Tanaka, M; Yamaura, T, 1998) |
| "We investigated the influence of T-593, a novel anti-ulcer agent, on the recurrence and relapse of cryocautery-induced gastric ulcer in rats, in comparison with the action of famotidine and ranitidine." | 3.70 | [Influence of T-593 on the recurrence and relapse of cryocautery-induced gastric ulcer in rats: sequential observation with an endoscope and histological evaluation]. ( Arai, H; Doi, Y; Hashiba, K; Marubuchi, S; Mizuo, M; Mori, Y; Syouji, M, 1998) |
| "The effect of T-593, a novel anti-ulcer agent, on the healing of cryocautery-induced rat gastric ulcer was investigated histologically in comparison with that of famotidine." | 3.70 | [Histological study on healing of cryocautery-induced rat gastric ulcer treated with T-593]. ( Arai, H; Doi, Y; Marubuchi, S; Mizuo, M; Mori, Y; Syoji, M; Urata, N, 1999) |
| "Gastric ulceration was evaluated following the orogastric administration of naproxen (80 mg/kg b." | 3.70 | Effect of naproxen on the hamster gastric antrum: ulceration, adaptation and efficacy of anti-ulcer drugs. ( Fitzpatrick, LR; Le, T; Sakurai, K, 1999) |
| " Chronic gastric ulcers were induced by serosa-searing with a hot metal bar, and the ulcer healing and recurrence after treatment with FRG-8813 or famotidine were evaluated by endoscopy for 160 days." | 3.70 | Effect of FRG-8813, a new-type histamine H(2)-receptor antagonist, on the recurrence of gastric ulcer after healing by drug treatment in rats. ( Ajioka, H; Matsuura, N; Miyake, H, 2000) |
| "We studied the detailed surface structure and changes in the regenerated mucosa during the course of healing of recurrent gastric ulcers treated with lansoprazole or famotidine, using a magnifying electronic endoscope (videoendoscope) and a dye contrast method." | 3.69 | Mucosal regeneration of gastric ulcer confirmed by electronic endoscopy. ( Fukuchi, S; Hashimoto, M; Hoshihara, Y; Iguchi, D; Kimura, T; Sugawara, K; Takemoto, T; Tanaka, T; Yamamoto, T, 1995) |
| "The effects of IGN-2098 on the healing process of acetic acid-induced gastric ulcer was investigated in comparison with the other histamine H2-receptor antagonists, famotidine and roxatidine acetate HCl, in rats." | 3.69 | [Therapeutic effect of IGN-2098, a new antiulcer drug (H2-antagonist), in the ulcer diminishing period against acetic acid-induced gastric ulcer in rats]. ( Ikarashi, Y; Misaki, N; Ohba, S; Ohbayashi, S; Uchida, M, 1995) |
| ") inhibited mepirizole-induced duodenal ulcers." | 3.69 | YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. ( Akuzawa, S; Ito, H; Kamato, T; Kobayashi, A; Miyata, K; Nagakura, Y; Nishida, A; Takinami, Y; Yamano, M; Yuki, H, 1994) |
| "Healing-promoting actions of KU-1257 (N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl]urea, CAS 120958-90-9) were investigated in chronic gastric and duodenal ulcer models induced by acetic acid in rats and the effects were compared with those of famotidine and roxatidine acetate by gross or histological evaluation." | 3.68 | Healing-promoting action of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl]urea with dual action on chronic gastric and duodenal ulcers induced by acetic acid in rats. ( Aijima, H; Hamada, K; Nishino, K; Sekiguchi, H; Taga, F; Uchida, H, 1993) |
| "In order to evaluate the efficacity and tolerance of Famotidine in the treatment of gastric ulcer, in Lebanese patients, we conducted a prospective open study in twenty one patients with benign gastric ulcer." | 3.68 | [Famotidine in the treatment of stomach ulcer]. ( Khoury, K; Nassr, W; Sayegh, R, 1992) |
| " Gastric and duodenal ulcerations induced by cold stress plus indomethacin, restraint and water immersion stress, pylorus ligation or cysteamine were also inhibited by pretreatment with 2-B4O." | 3.68 | Effect of an endogenous satiety substance, 2-buten-4-olide, on gastric acid secretion and experimental ulceration in rats. ( Arai, I; Muramatsu, M; Oomura, Y; Otomo, S; Shiraishi, T; Usuki-Ito, C, 1990) |
| "1 The effects of the new H2-receptor antagonist famotidine, administered orally, on gastric secretion and emptying as well as on experimentally-induced gastric and duodenal ulcers were studied in the rat." | 3.67 | Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine. ( Scarpignato, C; Tramacere, R; Zappia, L, 1987) |
| " Adverse events (AEs) were collected beginning at the first dose and continued through completion (54 weeks)." | 2.80 | One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| "Irsogladine has previously been shown to accelerate the healing of gastric ulcers after H." | 2.76 | Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. ( Abe, H; Arita, T; Fujioka, T; Kodama, M; Mizukami, K; Murakami, K; Okimoto, T; Shuto, M; Tanahashi, J, 2011) |
| "Famotidine was superior to rebamipide in treating NSAID-associated mucosal lesions." | 2.72 | Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy). ( Akiyama, K; Ann, T; Fukui, H; Haruma, K; Kikuchi, E; Kinoshita, Y; Kojima, H; Matsumoto, M; Mitoro, A; Miyauchi, Y; Nakayama, M; Ono, H; Sakurai, G; Takakura, Y; Yajima, H; Yamao, J; Yoshida, M; Yoshikawa, M, 2006) |
| "Famotidine was administered after lunch and before sleep, and the others were after breakfast and dinner." | 2.71 | Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. ( Furuta, T; Miura, S; Okudaira, K; Shirai, N; Sugimoto, M, 2005) |
| "When healing of gastric ulcers is observed using an electronic endoscope with a magnifying function, five types of regenerated mucosa can be distinguished." | 2.68 | Effects of lansoprazole on mucosal regeneration in patients with gastric ulcers: evaluation using an electronic endoscope with a magnifying function. ( Fukuchi, S; Hashimoto, M; Hoshihara, Y; Iguchi, D; Kimura, T; Sugawara, K; Takemoto, T; Tanaka, T; Yamamoto, T, 1995) |
| "Famotidine was well-tolerated and no serious clinical or laboratory adverse effects were judged to be related to this dosing regimen of famotidine." | 2.66 | Suppression of nocturnal acid secretion with famotidine accelerates gastric ulcer healing. ( Graham, DY; Knuff, TE; Lanza, FL; Levenson, HL; Lyon, DT; McCullough, AJ; Munsell, WP; Perozza, J; Roufail, WM; Sinar, DR, 1989) |
| "A multicentre, randomized, double-dummy control trial compared the efficacy of two famotidine dosage regimens for the treatment of acute gastric mucosal lesions." | 2.66 | Clinical evaluation of 20 mg/day famotidine in the treatment of acute gastric mucosal lesions. ( Miwa, T, 1989) |
| "Ibuprofen/famotidine was generally well tolerated, with a tolerability profile consistent with those established for the individual agents." | 2.49 | Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. ( Deeks, ED, 2013) |
| "Gastric ulcer is relatively infrequent, and clinical trails are often based on small-sized samples." | 2.39 | Short-term treatment of gastric ulcer. A meta-analytical evaluation of blind trials. ( Battaglia, G; Di Mario, F; Grasso, G; Leandro, G; Vianello, F; Vigneri, S, 1996) |
| "Felodipine is a calcium channel blocker with antioxidant and anti-inflammatory properties." | 1.91 | Effect of felodipine on indomethacin-induced gastric ulcers in rats. ( Akbaş, EM; Akbaş, N; Gülaboğlu, M; Mammadov, R; Süleyman, B; Süleyman, H, 2023) |
| "Montelukast is an anti-asthmatic drug, a selective reversible cysteinyl leukotriene D4 receptor antagonist." | 1.39 | Histopathologic evaluation of anti-ulcerogenic effect of montelukast in indomethacin-induced experimental ulcer model. ( Cadırcı, E; Ozbakış-Dengiz, G; Yurdakan, G, 2013) |
| " The antiulcerogenic effects of erythropoietin may be related to its intrinsic ability to sustain the activities of free-radical scavenging enzymes and the bioavailability of glutathione." | 1.36 | The role of erythropoietin in the protection of gastric mucosa from indometacin-induced gastric injury and its relationship with oxidant and antioxidant parameters in rats. ( Albayrak, F; Albayrak, Y; Bayir, Y; Dursun, H; Halici, Z; Koc, F; Odabasoglu, F; Polat, B; Suleyman, H; Uyanik, A, 2010) |
| "Famotidine treatment did not lead to abnormal respiration, heart rate and blood pressure." | 1.35 | [Efficacy and safety of famotidine for the treatment of stress ulcers in neonates]. ( Wu, YY, 2008) |
| "In indomethacin-treated animals, esomeprazole was more effective than famotidine or the antioxidant melatonin in promoting ulcer healing." | 1.35 | Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment. ( Antonioli, L; Blandizzi, C; Colucci, R; Del Tacca, M; Fornai, M; Ghisu, N; Tuccori, M, 2009) |
| "Gastric ulcer is a multifaceted process including acid secretion, reactive oxygen species generation, prostaglandin inhibition, and extracellular matrix (ECM) degradation." | 1.34 | Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer. ( Ganguly, K; Kundu, P; Mishra, A; Pradeepkumar Singh, L; Swarnakar, S, 2007) |
| "Lafutidine pretreatment before WRS caused a significant increase in serum CGRP concentration compared with famotidine (lafutidine, 86." | 1.32 | Lafutidine, a novel histamine H2-receptor antagonist, increases serum calcitonin gene-related peptide in rats after water immersion-restraint stress. ( Ishihara, S; Kawashima, K; Kazumori, H; Kinoshita, Y; Ortega-Cava, CF; Rumi, MA; Sato, H; Yuki, M, 2003) |
| "Omeprazole was more effective than famotidine in keeping gastric pH high and lowering the total gastric acid output." | 1.32 | Omeprazole is more effective than famotidine for preventing acute gastritis in rats. ( Akturk, Z; Ekinci, H; Muftuoglu, T; Peker, O; Topaloglu, U; Unalmiser, S, 2004) |
| "Dimethylglycine did not produce any significant change in acid secretion, unlike famotidine." | 1.31 | Effect of dimethylglycine on gastric ulcers in rats. ( Hariganesh, K; Prathiba, J, 2000) |
| " This study was undertaken to determine whether patients with chronic use of H2-receptor antagonists (HRA) had demonstrable decreases in bone mineral density (BMD)." | 1.30 | Bone mineral density in patients taking H2-receptor antagonist. ( Adachi, Y; Iso, Y; Kitano, S; Matsumata, T; Shiota, E; Yoh, R, 1998) |
| "Lafutidine is a new type antiulcer agent with antisecretory and gastroprotective activities." | 1.30 | Antiulcer effect of lafutidine on indomethacin-induced gastric antral ulcers in refed rats. ( Aoyama, M; Arai, Y; Inaba, N; Nishizawa, A; Onodera, S; Sekine, Y; Shibata, M; Suzuki, T; Tanaka, M, 1999) |
| "Treatment with sulpiride (10-320 mg/kg, p." | 1.29 | Sulpiride specifically attenuates psychological stress-induced gastric lesions in rodents. ( Kuratani, K; Maeda, N; Nomura, K; Yamaguchi, I, 1995) |
| "Pretreatment with famotidine or omeprazole reduced lesion index, and the protective effects were equivalent to those of 1." | 1.29 | Effects of FK506, an immunosuppressive agent, on genesis of water-immersion stress-induced gastric lesions in rats. ( Goto, H; Hamajima, E; Hoshino, H; Ozawa, T; Sugiyama, S; Tsukamoto, Y, 1994) |
| "Famotidine is a potent H2 receptor antagonist containing a thiazole ring structure, thus differing chemically from cimetidine and ranitidine." | 1.27 | Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology. ( , 1987) |
| "Pretreatment with famotidine prevented decreases in levels of PGs, which are known to have cytoprotective effect, and also maintained PLase activity." | 1.27 | Effect of the H2-blocker famotidine on gastric mucosal prostaglandin levels in water immersion stress in rats. ( Goto, H; Nakazawa, S; Ozawa, T; Sugiyama, S; Takano, K, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (16.96) | 18.7374 |
| 1990's | 68 (39.77) | 18.2507 |
| 2000's | 44 (25.73) | 29.6817 |
| 2010's | 25 (14.62) | 24.3611 |
| 2020's | 5 (2.92) | 2.80 |
| Authors | Studies |
|---|---|
| Mahmoud, MF | 1 |
| Abdo, W | 1 |
| Nabil, M | 1 |
| Drissi, B | 1 |
| El-Shazly, AM | 1 |
| Abdelfattah, MAO | 1 |
| Sobeh, M | 1 |
| Akbaş, N | 1 |
| Süleyman, B | 2 |
| Mammadov, R | 1 |
| Gülaboğlu, M | 2 |
| Akbaş, EM | 1 |
| Süleyman, H | 6 |
| Basha, M | 1 |
| Salama, A | 1 |
| Noshi, SH | 1 |
| Calik, I | 1 |
| Yayla, M | 1 |
| Cinar, I | 1 |
| Cadirci, E | 4 |
| Albayrak, A | 2 |
| Sirin, B | 1 |
| Calik, M | 1 |
| Halici, Z | 5 |
| Matsueda, K | 1 |
| Toyokawa, T | 1 |
| Sakata, M | 1 |
| Fujita, I | 1 |
| Horii, J | 1 |
| Abe, Y | 1 |
| Araki, T | 1 |
| Wong, GLH | 1 |
| Lau, LHS | 1 |
| Ching, JYL | 1 |
| Tse, YK | 1 |
| Ling, RHY | 1 |
| Wong, VWS | 1 |
| Chiu, PWY | 1 |
| Lau, JYW | 1 |
| Chan, FKL | 1 |
| Kuan, R | 1 |
| Holt, RJ | 5 |
| Johnson, KE | 1 |
| Kent, JD | 5 |
| Peura, DA | 1 |
| Malone, D | 1 |
| Deeks, ED | 1 |
| Ozbakış-Dengiz, G | 1 |
| Yurdakan, G | 1 |
| Tuskey, A | 1 |
| Peura, D | 1 |
| Nichitaĭlo, ME | 1 |
| Bello, AE | 5 |
| Grahn, AY | 4 |
| Rice, P | 1 |
| Ball, J | 2 |
| Taha, AS | 3 |
| Krylova, SG | 1 |
| Vymyatnina, ZK | 1 |
| Zueva, EP | 1 |
| Amosova, EN | 1 |
| Razina, TG | 1 |
| Litvinenko, VI | 1 |
| Fornai, M | 3 |
| Colucci, R | 3 |
| Antonioli, L | 3 |
| Ghisu, N | 2 |
| Tuccori, M | 3 |
| Blandizzi, C | 3 |
| Del Tacca, M | 2 |
| Wu, YY | 1 |
| Bilici, M | 1 |
| Ozturk, C | 1 |
| Dursun, H | 3 |
| Albayrak, F | 2 |
| Saglam, MB | 1 |
| Uyanik, A | 2 |
| Tekin, SB | 1 |
| Polat, B | 3 |
| Koc, F | 2 |
| Hacimuftuoglu, A | 1 |
| Bayir, Y | 2 |
| Lazebnik, LB | 1 |
| Drozdov, VN | 1 |
| Kim, VA | 1 |
| Kim, YJ | 1 |
| Cheon, JH | 2 |
| Lee, SK | 1 |
| Kim, JH | 1 |
| Lee, YC | 1 |
| Tolstikova, TG | 1 |
| Zhukova, NA | 1 |
| Sorokina, IV | 1 |
| Dolgikh, MP | 1 |
| Ogorodnikova, TV | 1 |
| Borodavkina, MV | 1 |
| Dugina, YL | 1 |
| Sergeeva, SA | 1 |
| Nishino, M | 1 |
| Sugimoto, M | 2 |
| Kodaira, C | 1 |
| Yamade, M | 1 |
| Uotani, T | 1 |
| Shirai, N | 2 |
| Ikuma, M | 1 |
| Tanaka, T | 3 |
| Sugimura, H | 1 |
| Hishida, A | 1 |
| Furuta, T | 2 |
| Odabasoglu, F | 3 |
| Albayrak, Y | 2 |
| Nagaraju, R | 1 |
| Prathusha, AP | 1 |
| Subhash Chandra Bose, P | 1 |
| Kaza, R | 1 |
| Bharathi, K | 1 |
| Awwad, O | 1 |
| Ugolini, C | 1 |
| Fulceri, F | 1 |
| Natale, G | 1 |
| Basolo, F | 1 |
| Sugiyama, T | 1 |
| Yamawaki, H | 1 |
| Murakami, K | 1 |
| Okimoto, T | 1 |
| Kodama, M | 1 |
| Tanahashi, J | 1 |
| Mizukami, K | 1 |
| Shuto, M | 1 |
| Abe, H | 1 |
| Arita, T | 1 |
| Fujioka, T | 1 |
| Yigiter, M | 1 |
| Laine, L | 1 |
| Kivitz, AJ | 1 |
| Schiff, MH | 1 |
| Chan, FK | 1 |
| Takayama, S | 1 |
| Izuhara, C | 1 |
| Yamada, N | 1 |
| Yamanaka, S | 1 |
| Hashimoto, E | 1 |
| Kaneko, S | 1 |
| Takeuchi, K | 1 |
| Tomita, T | 1 |
| Kim, Y | 1 |
| Yamasaki, T | 1 |
| Okugawa, T | 1 |
| Kondo, T | 1 |
| Toyoshima, F | 1 |
| Sakurai, J | 1 |
| Tanaka, J | 3 |
| Morita, T | 1 |
| Oshima, T | 1 |
| Fukui, H | 2 |
| Hori, K | 1 |
| Watari, J | 1 |
| Matsumoto, T | 2 |
| Miwa, H | 1 |
| Shcherbynina, MB | 1 |
| Grinevich, VB | 1 |
| Uspenskiĭ, IuP | 1 |
| Shabanova, GZh | 1 |
| Sablin, OA | 1 |
| Shcherbina, NN | 1 |
| Ohsawa, T | 1 |
| Hirata, W | 1 |
| Higichi, S | 1 |
| Sato, H | 1 |
| Kawashima, K | 1 |
| Yuki, M | 1 |
| Kazumori, H | 1 |
| Rumi, MA | 1 |
| Ortega-Cava, CF | 1 |
| Ishihara, S | 1 |
| Kinoshita, Y | 2 |
| Horie, S | 2 |
| Yamamoto, H | 2 |
| Michael, GJ | 1 |
| Uchida, M | 3 |
| Belai, A | 1 |
| Watanabe, K | 2 |
| Priestley, JV | 1 |
| Murayama, T | 2 |
| Sudheer Kumar, M | 1 |
| Sridhar Reddy, B | 1 |
| Kiran Babu, S | 1 |
| Bhilegaonkar, PM | 1 |
| Shirwaikar, A | 1 |
| Unnikrishnan, MK | 1 |
| Topaloglu, U | 1 |
| Muftuoglu, T | 1 |
| Akturk, Z | 1 |
| Ekinci, H | 1 |
| Peker, O | 1 |
| Unalmiser, S | 1 |
| Horiuchi, Y | 1 |
| Bae, SJ | 1 |
| Katayama, I | 1 |
| Hayashi, Y | 1 |
| Shiomi, M | 1 |
| Kamisako, T | 1 |
| Yutani, I | 1 |
| Yoshimoto, R | 1 |
| Kudo, M | 1 |
| Fujii, R | 1 |
| Korukov, B | 1 |
| Ognianov, S | 1 |
| Kostadinova, R | 1 |
| Gerzilov, P | 1 |
| Ivanov, A | 1 |
| Iarŭmov, N | 1 |
| Okudaira, K | 1 |
| Miura, S | 1 |
| Yamaguchi, Y | 1 |
| Katsumi, N | 1 |
| Tauchi, M | 1 |
| Toki, M | 1 |
| Nakamura, K | 1 |
| Aoki, K | 1 |
| Morita, Y | 1 |
| Miura, M | 1 |
| Morozumi, K | 1 |
| Ishida, H | 1 |
| Takahashi, S | 1 |
| Ozbakiş Dengiz, G | 1 |
| Gürsan, N | 1 |
| Higuchi, K | 3 |
| Watanabe, T | 2 |
| Tominaga, K | 3 |
| Shiba, M | 2 |
| Nakagawa, K | 2 |
| Uno, H | 2 |
| Kitada, K | 2 |
| Satoh, H | 3 |
| Chono, S | 2 |
| Uchida, T | 1 |
| Fujiwara, Y | 2 |
| Arakawa, T | 3 |
| Qin, Z | 1 |
| Chen, C | 1 |
| Ye, BD | 1 |
| Choi, KD | 1 |
| Kim, SG | 1 |
| Kim, JS | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Umamaheswari, M | 1 |
| Asokkumar, K | 1 |
| Rathidevi, R | 1 |
| Sivashanmugam, AT | 1 |
| Subhadradevi, V | 1 |
| Ravi, TK | 1 |
| Oshitani, N | 2 |
| Harada, N | 1 |
| Okajima, K | 1 |
| Yamao, J | 1 |
| Kikuchi, E | 1 |
| Matsumoto, M | 1 |
| Nakayama, M | 1 |
| Ann, T | 1 |
| Kojima, H | 1 |
| Mitoro, A | 1 |
| Yoshida, M | 1 |
| Yoshikawa, M | 1 |
| Yajima, H | 1 |
| Miyauchi, Y | 1 |
| Ono, H | 1 |
| Akiyama, K | 1 |
| Sakurai, G | 1 |
| Haruma, K | 1 |
| Takakura, Y | 1 |
| Spasov, AA | 1 |
| Chernikov, MV | 1 |
| Speranskaia, AS | 1 |
| Zaĭchenko, SI | 1 |
| Pradeepkumar Singh, L | 1 |
| Kundu, P | 1 |
| Ganguly, K | 1 |
| Mishra, A | 1 |
| Swarnakar, S | 1 |
| Dengiz, GO | 1 |
| Takeda, M | 2 |
| Takagi, T | 1 |
| Yashima, Y | 1 |
| Maeno, H | 1 |
| Mori, H | 1 |
| Nomura, K | 2 |
| Maeda, N | 2 |
| Kuratani, K | 2 |
| Yamaguchi, I | 3 |
| Hamajima, E | 1 |
| Sugiyama, S | 2 |
| Hoshino, H | 1 |
| Goto, H | 3 |
| Tsukamoto, Y | 2 |
| Ozawa, T | 2 |
| Tsuji, S | 1 |
| Kawano, S | 2 |
| Higashi, T | 1 |
| Mukuda, T | 1 |
| Imaizumi, T | 1 |
| Tatsumi, T | 1 |
| Miura, N | 1 |
| Miyajima, K | 1 |
| Fukuda, M | 1 |
| Noguchi, M | 1 |
| Sakaguchi, M | 1 |
| Ashida, K | 1 |
| Umegaki, E | 1 |
| Miyoshi, H | 1 |
| Katsu, K | 1 |
| Okai, T | 1 |
| Sawabu, N | 1 |
| Songür, Y | 1 |
| Motoo, Y | 1 |
| Watanabe, H | 1 |
| Hashimoto, M | 2 |
| Hoshihara, Y | 2 |
| Yamamoto, T | 2 |
| Kimura, T | 2 |
| Iguchi, D | 2 |
| Sugawara, K | 2 |
| Fukuchi, S | 2 |
| Takemoto, T | 3 |
| Gschwantler, M | 3 |
| Weiss, W | 4 |
| Penka, G | 1 |
| Zirm, B | 1 |
| Stupnicki, T | 1 |
| Spath, P | 1 |
| Ikarashi, Y | 1 |
| Ohba, S | 1 |
| Ohbayashi, S | 1 |
| Misaki, N | 1 |
| Yoshino, T | 1 |
| Mori, K | 1 |
| Yokoyama, K | 1 |
| Suga, Y | 1 |
| Kishiro, I | 1 |
| Tsurui, M | 1 |
| Heiselman, DE | 1 |
| Hulisz, DT | 1 |
| Fricker, R | 1 |
| Bredle, DL | 1 |
| Black, LD | 1 |
| Tanaka, M | 4 |
| Maruoka, A | 1 |
| Chijiiwa, Y | 1 |
| Nawata, H | 1 |
| Behrens, R | 1 |
| Hofbeck, M | 1 |
| Singer, H | 1 |
| Scharf, J | 1 |
| Rupprecht, T | 1 |
| Fujimoto, K | 1 |
| Iwakiri, R | 1 |
| Koyama, T | 1 |
| Sakata, H | 1 |
| Ohyama, T | 1 |
| Mizuguchi, M | 1 |
| Tokunaga, O | 1 |
| Nishida, A | 2 |
| Takinami, Y | 1 |
| Yuki, H | 1 |
| Kobayashi, A | 1 |
| Akuzawa, S | 1 |
| Kamato, T | 2 |
| Ito, H | 1 |
| Yamano, M | 1 |
| Nagakura, Y | 1 |
| Miyata, K | 2 |
| Savarino, V | 3 |
| Mela, GS | 3 |
| Zentilin, P | 1 |
| Vigneri, S | 2 |
| Celle, G | 3 |
| Matsunaga, Y | 1 |
| Yamamoto, O | 1 |
| Ueki, S | 1 |
| Haga, N | 1 |
| Mizusawa, F | 1 |
| Mizumoto, A | 1 |
| Sano, I | 1 |
| Itoh, Z | 1 |
| Sekiguchi, H | 1 |
| Hamada, K | 1 |
| Aijima, H | 1 |
| Taga, F | 1 |
| Uchida, H | 1 |
| Nishino, K | 1 |
| Yoshinaga, M | 1 |
| Nakate, S | 1 |
| Motomura, S | 1 |
| Sugimura, T | 1 |
| Sasaki, I | 1 |
| Tsuneyoshi, M | 1 |
| Sakaki, N | 1 |
| Arita, M | 2 |
| Okada, M | 2 |
| Motomura, A | 1 |
| Matsui, T | 1 |
| Hosiko, K | 1 |
| Yao, T | 2 |
| Yamada, T | 1 |
| Kobayashi, K | 1 |
| Hudson, N | 1 |
| Hawkey, CJ | 1 |
| Swannell, AJ | 1 |
| Trye, PN | 1 |
| Cottrell, J | 1 |
| Mann, SG | 2 |
| Simon, TJ | 1 |
| Sturrock, RD | 1 |
| Russell, RI | 1 |
| Di Mario, F | 1 |
| Battaglia, G | 1 |
| Leandro, G | 1 |
| Grasso, G | 1 |
| Vianello, F | 1 |
| Liss, GM | 1 |
| Zeltsman, D | 1 |
| Rowland, M | 1 |
| Shanavas, Z | 1 |
| Kerstein, MD | 1 |
| Graham, DY | 2 |
| Pal'tsev, AI | 1 |
| Maslennikova, TA | 1 |
| Grigor'ev, PI | 1 |
| Grinberg, AA | 1 |
| Toguzova, DA | 2 |
| Iakovenko, AV | 1 |
| Lopatina, IV | 1 |
| Suzuki, M | 1 |
| Mori, M | 1 |
| Miyayama, A | 1 |
| Iwai, N | 1 |
| Tsunematsu, N | 1 |
| Oonuki, M | 1 |
| Suzuki, H | 1 |
| Hibi, T | 1 |
| Ishii, H | 1 |
| Adachi, Y | 1 |
| Shiota, E | 1 |
| Matsumata, T | 1 |
| Iso, Y | 1 |
| Yoh, R | 1 |
| Kitano, S | 1 |
| Onodera, S | 2 |
| Aoyama, M | 2 |
| Arai, Y | 2 |
| Shibata, M | 3 |
| Yamaura, T | 2 |
| Ohnishi, H | 2 |
| Inalöz, SS | 1 |
| Goral, V | 1 |
| Sari, I | 1 |
| Dragosics, B | 3 |
| Wurzer, H | 2 |
| Brandstätter, G | 2 |
| Bogachev, RS | 1 |
| Levina, ZK | 1 |
| Mori, Y | 3 |
| Doi, Y | 2 |
| Hashiba, K | 1 |
| Syouji, M | 1 |
| Mizuo, M | 2 |
| Marubuchi, S | 2 |
| Arai, H | 2 |
| Lad, R | 1 |
| Armstrong, D | 1 |
| Ohta, Y | 1 |
| Kobayashi, T | 1 |
| Ishiguro, I | 1 |
| Alekseenko, SA | 1 |
| Timoshin, SS | 1 |
| Amagase, K | 1 |
| Ikeda, K | 1 |
| Okabe, S | 2 |
| Urata, N | 1 |
| Syoji, M | 1 |
| Inaba, N | 1 |
| Suzuki, T | 2 |
| Nishizawa, A | 1 |
| Sekine, Y | 1 |
| Sasakii, M | 1 |
| Joh, T | 1 |
| Yokoyama, Y | 1 |
| Seno, K | 1 |
| Tsuchida, K | 1 |
| Kurokawa, T | 1 |
| Itoh, M | 1 |
| Schütze, K | 1 |
| Hirschl, AM | 1 |
| Pasching, E | 1 |
| Wimmer, M | 1 |
| Klimpfinger, M | 1 |
| Oberhuber, G | 1 |
| Hentschel, E | 4 |
| Fitzpatrick, LR | 2 |
| Sakurai, K | 1 |
| Le, T | 1 |
| Wu, CS | 1 |
| Wang, SH | 1 |
| Chen, PC | 1 |
| Wu, VC | 1 |
| Yoshida, N | 1 |
| Yoshikawa, T | 1 |
| Tanaka, Y | 1 |
| Fujita, N | 1 |
| Kassai, K | 1 |
| Naito, Y | 1 |
| Kondo, M | 1 |
| Pleshkov, VG | 1 |
| Afanas'ev, VN | 1 |
| Ovsiankin, AV | 1 |
| Mansurova, FKh | 1 |
| Kadyrov, DM | 1 |
| Odinaev, RI | 1 |
| Ishankulova, DM | 1 |
| Ajioka, H | 1 |
| Miyake, H | 1 |
| Matsuura, N | 1 |
| Hariganesh, K | 1 |
| Prathiba, J | 1 |
| Sener-Muratoğlu, G | 1 |
| Paskaloğlu, K | 1 |
| Arbak, S | 1 |
| Hürdağ, C | 1 |
| Ayanoğlu-Dülger, G | 1 |
| Shlevkov, BA | 1 |
| Abramova, LA | 1 |
| Yuan, RY | 1 |
| Kao, CR | 1 |
| Sheu, JJ | 1 |
| Chen, CH | 1 |
| Ho, CS | 1 |
| Tsuchiya, S | 1 |
| Demirezer, LO | 1 |
| Büyükokuroglu, ME | 1 |
| Akcay, MF | 1 |
| Gepdiremen, A | 1 |
| Banoglu, ZN | 1 |
| Göçer, F | 1 |
| Nikiforov, PA | 1 |
| Bazarova, MA | 1 |
| Nikitina, SA | 1 |
| Osin, VL | 1 |
| Shugurov, VA | 1 |
| Esaki, M | 1 |
| Aoyagi, K | 1 |
| Kuwano, Y | 1 |
| Shimizu, M | 1 |
| Fujishima, M | 1 |
| Mizokami, Y | 1 |
| Shiraishi, T | 2 |
| Otsubo, T | 1 |
| Nakamura, H | 1 |
| Miyazawa, K | 1 |
| Narushima, K | 1 |
| Matsuoka, T | 1 |
| Vakhrushev, IaM | 1 |
| Muravtseva, OV | 1 |
| Jakubowska, A | 1 |
| Martin, GE | 1 |
| Davis, M | 1 |
| Jaye, MC | 1 |
| Dionne, CA | 1 |
| Sayegh, R | 1 |
| Khoury, K | 1 |
| Nassr, W | 1 |
| Ogawa, N | 1 |
| Hase, S | 1 |
| Arisawa, T | 1 |
| Asai, J | 1 |
| Yamazaki, M | 1 |
| Kodama, H | 1 |
| Okulski, G | 1 |
| Espitia, VR | 1 |
| Yamaoka, K | 1 |
| Kisu, T | 1 |
| Sakurai, T | 1 |
| Okabe, N | 1 |
| Iida, M | 1 |
| Okada, Y | 1 |
| Koga, T | 1 |
| Okuhira, M | 1 |
| Nakano, T | 1 |
| Kitajima, T | 1 |
| Maruoka, M | 1 |
| Hiramatsu, A | 1 |
| Mizuno, T | 1 |
| Inoue, K | 1 |
| Hoffenberg, P | 1 |
| Reyes, V | 1 |
| Palma, J | 1 |
| Ossa, P | 1 |
| Maggiolo, P | 1 |
| Klinger, J | 1 |
| Inatomi, N | 1 |
| Nagaya, H | 1 |
| Takami, K | 1 |
| Shino, A | 1 |
| Berlin, RG | 1 |
| Root, JK | 2 |
| Cook, TJ | 1 |
| Lipsy, RJ | 1 |
| Fennerty, B | 1 |
| Fagan, TC | 1 |
| Nishida, T | 1 |
| Igata, H | 1 |
| Takagi, K | 1 |
| Sekine, A | 1 |
| Nishikawa, M | 1 |
| Chida, Y | 1 |
| Honda, K | 1 |
| Sawant, PD | 1 |
| Nanivadekar, SA | 1 |
| Patel, HD | 1 |
| Shroff, CP | 1 |
| Oke, VG | 1 |
| Jha, RJ | 1 |
| Bowalekar, SK | 1 |
| Navani, SR | 1 |
| Raghu, CN | 1 |
| Dammann, HG | 7 |
| Arai, I | 1 |
| Usuki-Ito, C | 1 |
| Muramatsu, M | 1 |
| Otomo, S | 1 |
| Oomura, Y | 1 |
| Yoshinaga, E | 1 |
| Cochran, KM | 1 |
| Cockel, R | 1 |
| Crowe, J | 1 |
| Dickinson, RJ | 1 |
| Gent, AE | 1 |
| Kennedy, NP | 1 |
| Royston, CM | 1 |
| Cedar, E | 1 |
| Gitnick, G | 1 |
| Brazer, SR | 1 |
| Tyor, MP | 1 |
| Pancotto, FS | 1 |
| Brice, RS | 1 |
| Garbutt, JT | 1 |
| Wildermann, NM | 1 |
| Harrell, FE | 1 |
| Pryor, DB | 1 |
| Liss, CL | 1 |
| McCullough, AJ | 1 |
| Knuff, TE | 1 |
| Lanza, FL | 1 |
| Levenson, HL | 1 |
| Lyon, DT | 2 |
| Munsell, WP | 1 |
| Perozza, J | 1 |
| Roufail, WM | 1 |
| Sinar, DR | 1 |
| Ito, A | 1 |
| Nagase, H | 1 |
| Miwa, T | 1 |
| Barbara, L | 3 |
| Bianchi-Porro, G | 1 |
| Cheli, R | 2 |
| Müller, P | 6 |
| Paoluzzi, P | 1 |
| Simon, B | 6 |
| Walter, TA | 3 |
| Paoluzi, P | 1 |
| Torsoli, A | 1 |
| Bianchi Porro, G | 2 |
| Lazzaroni, M | 1 |
| Corinaldesi, R | 2 |
| Blasi, A | 1 |
| Mangiameli, A | 1 |
| Carratelli, L | 1 |
| Friedl, W | 1 |
| Krier, C | 1 |
| Scarpignato, C | 1 |
| Tramacere, R | 1 |
| Zappia, L | 1 |
| Pasquali, R | 1 |
| Paternico, A | 1 |
| Stanghellini, V | 1 |
| Paparo, GF | 1 |
| Ricci Maccarini, M | 1 |
| Takano, K | 1 |
| Nakazawa, S | 1 |
| Tomasko, MA | 1 |
| Luskin, AT | 1 |
| Pounder, R | 1 |
| Bonardelli, P | 1 |
| Fujita, Y | 1 |
| Fujita, R | 1 |
| Sugata, F | 1 |
| Yoshimura, Y | 1 |
| Yasutake, K | 1 |
| Imamura, Y | 1 |
| Oimomi, M | 1 |
| Haga, K | 1 |
| Asano, K | 1 |
| Osuga, K | 1 |
| Maruyama, Y | 1 |
| Henann, NE | 1 |
| Carpenter, DU | 1 |
| Janda, SM | 1 |
| Sato, N | 1 |
| Kamada, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial[NCT01180179] | Phase 4 | 228 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment[NCT00984815] | Phase 3 | 86 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450658] | Phase 3 | 627 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450216] | Phase 3 | 906 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The non-pain symptom scale of the SODA questionnaire ranges from 7 - 35. Change from baseline compares the score at Week 54 to the baseline score for each participant that completed the non-pain symptom questions of the SODA questionnaire at baseline and Week 54. Higher scores indicate greater symptom severity and therefore a negative mean change from baseline is indicative of an improvement in symptoms. (NCT00984815)
Timeframe: Baseline and 54 Weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| HZT-501 | -1.44 |
The pain intensity scale of the SODA questionnaire ranges from 2 - 47. Change from baseline compares the score at Week 54 to the baseline score for each participant who completed the pain intensity questions of the SODA questionnaire at baseline and Week 54. Higher scores indicate greater symptom severity and therefore a negative mean change from baseline is indicative of an improvement in symptoms. (NCT00984815)
Timeframe: Baseline and 54 Weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| HZT-501 | -3.22 |
The satisfaction with dyspepsia-related health scale of the SODA questionnaire ranges from 2 - 23. Change from baseline compares the score at Week 54 to the baseline score for each participant who completed the Satisfaction questions of the SODA questionnaire at baseline and Week 54. A positive change from baseline in the SODA satisfaction scale represents a participant's overall improved satisfaction with their dyspepsia-related health. (NCT00984815)
Timeframe: Baseline and 54 Weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| HZT-501 | 2.69 |
(NCT00984815)
Timeframe: 54 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 76 |
The secondary efficacy endpoint was the number of subjects with duodenal ulcer at any time throughout the 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 3 |
| Ibuprofen | 9 |
The secondary efficacy endpoint was the number of subjects with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 37 |
| Ibuprofen | 34 |
The primary efficacy endpoint was the number of subjects with upper gastrointestinal (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 40 |
| Ibuprofen | 38 |
The secondary efficacy endpoint was the number of subjects developing a NSAID-associated serious GI complication at any time throughout 6 months of treatment. A NSAID-associated serious GI complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or GI bleeding. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 0 |
| Ibuprofen | 0 |
The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 8 |
| Ibuprofen | 14 |
The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 55 |
| Ibuprofen | 52 |
The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 63 |
| Ibuprofen | 61 |
The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding. (NCT00450216)
Timeframe: 24 weeks
| Intervention | particpants (Number) |
|---|---|
| HZT-501 | 3 |
| Ibuprofen | 0 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
11 reviews available for famotidine and Gastric Ulcer
| Article | Year |
|---|---|
Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Drug Interactions; Duodenal Ulcer; Famot | 2013 |
The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Therapy, Combination; Famotidine; G | 2013 |
Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Combinations; Duodenal Ulcer; Famot | 2014 |
[Mucoprotective drugs and aspirin-induced gastric injury].
Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Famotidine; Huma | 2010 |
Short-term treatment of gastric ulcer. A meta-analytical evaluation of blind trials.
Topics: Antacids; Anti-Ulcer Agents; Bismuth; Cimetidine; Controlled Clinical Trials as Topic; Famotidine; H | 1996 |
Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Gastric Juic | 1999 |
Clinical review of histamine2 receptor antagonists.
Topics: Cimetidine; Drug Interactions; Duodenal Ulcer; Famotidine; Histamine H2 Antagonists; Humans; Nizatid | 1990 |
Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview.
Topics: Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Famotidine; Humans; Product Surveilla | 1990 |
Famotidine in the USA: a review of efficacy studies.
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Gastric Acid; Gastric Juice; Histamine H2 Antagonists | 1989 |
Histamine H2-receptor antagonists.
Topics: Animals; Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Famotidine; Histamine H2 Ant | 1988 |
Double pylorus accompanied by gastric ulcer resistant to H2-receptor antagonist--a case report and review of the literature.
Topics: Drug Resistance; Famotidine; Female; Histamine H2 Antagonists; Humans; Middle Aged; Pylorus; Stomach | 1988 |
52 trials available for famotidine and Gastric Ulcer
| Article | Year |
|---|---|
Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antag | 2020 |
One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Drug | 2015 |
One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Drug | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
[Efficiency of famotidin in prophylaxis of NSAIDs-induced gastropathy: result of multicenter research ZASLON-1 (protection of gastric mucosa from non-steroidal anti-inflammatory drugs].
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Dic | 2009 |
Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Famotidine; | 2010 |
Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer | 2011 |
Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study.
Topics: Aged; Alcohol Drinking; Anti-Ulcer Agents; Drug Administration Schedule; Famotidine; Female; Helicob | 2011 |
Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2012 |
Prospective randomized controlled trial to compare the effects of omeprazole and famotidine in preventing delayed bleeding and promoting ulcer healing after endoscopic submucosal dissection.
Topics: Adenocarcinoma; Adenoma; Aged; Aged, 80 and over; Analysis of Variance; Famotidine; Female; Gastric | 2012 |
[Study on the efficacy of famotidine (Quamatel) in the complex treatment of erosive gastroduodenitis, stress stomach ulcer and peptic duodenal ulcer].
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Bulgaria; Duodenal Ulcer; Famotidine; Female; Gas | 2004 |
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP | 2005 |
A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration.
Topics: Aged; Anti-Ulcer Agents; Cost-Benefit Analysis; Endoscopy, Gastrointestinal; Famotidine; Female; Gas | 2005 |
Effects of ranitidine on quality of gastric ulcer healing compared with famotidine: a randomized, controlled, multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Famotidine; Female; Gastric Mucosa; Gastroscopy; | 2005 |
Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial.
Topics: Anti-Ulcer Agents; Famotidine; Female; Gastric Mucosa; Gastrointestinal Hemorrhage; Gastroscopy; Hum | 2006 |
Lafutidine can improve the quality of gastric ulcer healing in humans: a randomized, controlled, multicenter trial.
Topics: Acetamides; Adult; Aged; Anti-Ulcer Agents; Drug Administration Schedule; Famotidine; Female; Gastro | 2006 |
Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy).
Topics: Adult; Aged; Alanine; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Famotidine; Female; Gastric Mu | 2006 |
Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Famotidine; Female; Fibroblast Growth Fa | 1995 |
Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Depression, Chemical; Famot | 1995 |
Comparison of lansoprazole and famotidine for gastric ulcer by endoscopic ultrasonography: a preliminary trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Famotidi | 1995 |
Effects of lansoprazole on mucosal regeneration in patients with gastric ulcers: evaluation using an electronic endoscope with a magnifying function.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Gastric | 1995 |
Eradication of Helicobacter pylori by a combination of amoxicillin and famotidine.
Topics: Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Gastritis; Helicobacter | 1995 |
Efficacy of famotidine in patients with acute gastric mucosal injury after continuous infusion of cisplatin plus vindesine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Flow Velocity; Carcinoma, Non-Sma | 1995 |
Randomized comparison of gastric pH control with intermittent and continuous intravenous infusion of famotidine in ICU patients.
Topics: Aged; Analysis of Variance; Double-Blind Method; Drug Administration Schedule; Famotidine; Female; H | 1995 |
Frequency of stress lesions of the upper gastrointestinal tract in paediatric patients after cardiac surgery: effects of prophylaxis.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Famotidine; Female; Heart Defects, Congenit | 1994 |
Comparison of the effects of single morning and single bedtime doses of famotidine on intragastric acidity in patients with gastric ulcer.
Topics: Drug Administration Schedule; Famotidine; Female; Gastric Acidity Determination; Humans; Hydrogen-Io | 1994 |
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthriti | 1996 |
Eradication of Helicobacter pylori by a 1-week course of famotidine, amoxicillin and clarithromycin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Famotidi | 1998 |
[The effect of histamine H2 receptor blockers on reparative processes in the gastric mucosa of patients with gastric peptic ulcer].
Topics: Adult; Antacids; Anti-Ulcer Agents; Autoradiography; Biopsy; Cimetidine; Famotidine; Female; Gastric | 1999 |
The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Helicob | 1999 |
Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Drug Resis | 1999 |
Does famotidine have similar efficacy to misoprostol in the treatment of non-steroidal anti-inflammatory drug-induced gastropathy?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Famotidine; Female; Gastroint | 1998 |
Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans.
Topics: Aged; Anti-Ulcer Agents; Endoscopy; Famotidine; Female; Fibroblast Growth Factor 2; Humans; Male; Mi | 2002 |
[Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adolescent; Adult; Aged; Anti-Ul | 1992 |
[Therapy of peptic ulcers with famotidine. Report of experiences with an open clinical study].
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Dose-Response Relationship, Drug; Drug Administrati | 1992 |
A comparative study of once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating gastric ulcers.
Topics: Adult; Aged; Drug Administration Schedule; Famotidine; Female; Gastroscopy; Humans; Male; Middle Age | 1992 |
[Treatment of gastric ulcer with sucralfate and famotidine].
Topics: Adult; Aged; Double-Blind Method; Drug Administration Schedule; Famotidine; Female; Gastric Acid; Hu | 1991 |
Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcer.
Topics: Adult; Double-Blind Method; Famotidine; Female; Humans; Male; Middle Aged; Recurrence; Stomach Ulcer | 1991 |
Double-blind comparison of the safety and efficacy of famotidine with ranitidine in patients with endoscopically diagnosed peptic ulcer.
Topics: Adult; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Humans; India; Male; Ranitidine; Sto | 1990 |
Comparison of 40 mg famotidine nightly and 150 mg ranitidine b.d.: ulcer healing and symptom relief in benign gastric ulcer.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Famotidine; Female; Gastroscopy; Humans; Male; Middle | 1989 |
Randomized, double-blind comparison of famotidine with ranitidine in treatment of acute, benign gastric ulcer disease. Community-based study coupled with a patient registry.
Topics: Clinical Trials as Topic; Double-Blind Method; Famotidine; Female; Histamine H2 Antagonists; Humans; | 1989 |
Suppression of nocturnal acid secretion with famotidine accelerates gastric ulcer healing.
Topics: Clinical Trials as Topic; Double-Blind Method; Famotidine; Female; Gastric Acid; Histamine H2 Antago | 1989 |
Clinical evaluation of 20 mg/day famotidine in the treatment of acute gastric mucosal lesions.
Topics: Adult; Aged; Anti-Ulcer Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Famotidi | 1989 |
[Accelerated healing of ulcus ventriculi by a single evening dose of famotidine. Results of an Austrian-German-Italian multicenter study].
Topics: Adolescent; Adult; Aged; Austria; Clinical Trials as Topic; Double-Blind Method; Drug Administration | 1985 |
Famotidine (MK-208) in the treatment of gastric ulcer. Results of a multicenter double-blind controlled study.
Topics: Adolescent; Adult; Aged; Antacids; Circadian Rhythm; Clinical Trials as Topic; Double-Blind Method; | 1985 |
Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience.
Topics: Acute Disease; Chronic Disease; Cimetidine; Circadian Rhythm; Clinical Trials as Topic; Double-Blind | 1985 |
[I.v. famotidine versus i.v. ranitidine: intragastric pH behavior in surgical intensive care patients].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Critical Care; Double-Blind Method; Famotidine; G | 1985 |
Efficacy and safety of famotidine in the management of benign gastric ulcers.
Topics: Adult; Clinical Trials as Topic; Famotidine; Female; Histamine H2 Antagonists; Humans; Male; Middle | 1986 |
Famotidine once-a-day in the therapy of acute, benign gastric ulcer: a worldwide experience.
Topics: Acute Disease; Adult; Antacids; Double-Blind Method; Drug Administration Schedule; Famotidine; Hista | 1987 |
Histamine H2-receptor antagonists.
Topics: Animals; Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Famotidine; Histamine H2 Ant | 1988 |
Famotidine: proven once-a-day treatment for gastric ulcer.
Topics: Adult; Anti-Ulcer Agents; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedul | 1987 |
Famotidine: nocturnal administration for gastric ulcer healing. Results of multicenter trials in Austria and Germany.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule | 1985 |
109 other studies available for famotidine and Gastric Ulcer
| Article | Year |
|---|---|
Apple (Malus domestica Borkh) leaves attenuate indomethacin-induced gastric ulcer in rats.
Topics: Animals; Cyclooxygenase 2; Cytokines; Famotidine; Gastric Mucosa; Gastritis; HSP70 Heat-Shock Protei | 2023 |
Effect of felodipine on indomethacin-induced gastric ulcers in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Famotidine; Felodipine; Indomethacin | 2023 |
Soluplus
Topics: Animals; Chemistry, Pharmaceutical; Drug Compounding; Excipients; Famotidine; Inflammation; Male; Po | 2020 |
LP44 (4-[2-(methylthio)phenyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide) exerts anti-ulcer effects via 5-hydroxytryptamine receptor 7 activation on indomethacin-induced gastric ulcers in rats.
Topics: Amides; Animals; Famotidine; Gene Expression; Indomethacin; Male; Nitric Oxide Synthase Type III; Ph | 2020 |
Hemorrhagic Stress-induced Gastric Ulcer in a Healthy Toddler.
Topics: Acute Disease; Endoscopy; Famotidine; Female; Gastrointestinal Hemorrhage; Humans; Infant; Peptic Ul | 2018 |
Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Drug Combinations | 2013 |
Histopathologic evaluation of anti-ulcerogenic effect of montelukast in indomethacin-induced experimental ulcer model.
Topics: Acetates; Animals; Anti-Ulcer Agents; Cyclopropanes; Disease Models, Animal; Famotidine; Gastric Muc | 2013 |
[Prophylaxis of an acute postoperative pancreatitis and the stress ulcers occurrence after operations, performed on organs of hepatopancreatoduodenal zone, using miniinvasive and open access].
Topics: Acute Disease; Drug Administration Schedule; Drug Dosage Calculations; Duodenal Ulcer; Endoscopy, Ga | 2014 |
The ibuprofen-famotidine combined pill - a promise fulfilled.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dyspepsia; Famotidine; Female; Histamine H2 Antagonists; Hu | 2015 |
Effects of Cichorium Intybus L. Root Extract on Secretory Activity of the Stomach in Health and Ulcer Disease.
Topics: Animals; Anti-Ulcer Agents; Carbachol; Cichorium intybus; Dogs; Famotidine; Female; Gastric Fistula; | 2015 |
Effects of pantoprazole on ulcer healing delay associated with NSAID treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroid | 2009 |
[Efficacy and safety of famotidine for the treatment of stress ulcers in neonates].
Topics: Anti-Ulcer Agents; Famotidine; Female; Gastric Acidity Determination; Histamine H2 Antagonists; Huma | 2008 |
Protective effect of mirtazapine on indomethacin-induced ulcer in rats and its relationship with oxidant and antioxidant parameters.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antidepressive Agents, Tricycli | 2009 |
Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antioxidants; Caspase 3; Dinopr | 2009 |
Comparative study on the gastroprotective potential of some antidepressants in indomethacin-induced ulcer in rats.
Topics: Animals; Anti-Ulcer Agents; Antidepressive Agents; Cyclohexanols; Famotidine; Indomethacin; Male; Ra | 2009 |
Antiulcer activity of preparations containing ultralow doses of antibodies in modeled chronic ulcer in rats.
Topics: Acetates; Animals; Anti-Ulcer Agents; Antibodies; Famotidine; Gastrins; Histamine; Male; Rats; Rats, | 2009 |
The role of erythropoietin in the protection of gastric mucosa from indometacin-induced gastric injury and its relationship with oxidant and antioxidant parameters in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antioxidants; Dose-Response Rel | 2010 |
Preparation and evaluation of famotidine polymorphs.
Topics: Animals; Anti-Ulcer Agents; Crystallization; Disease Models, Animal; Drug Stability; Excipients; Fam | 2010 |
Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce | 2011 |
Antiulcerative effect of dexmedetomidine on indomethacin-induced gastric ulcer in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2011 |
A fixed-dose combination ibuprofen and famotidine (Duexis).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Duodenal Ulcer; F | 2011 |
Editorial: single-tablet ibuprofen/double-dose famotidine for reduction of gastric and duodenal ulcers (REDUCE Trials): what can be reduced?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Huma | 2012 |
A new model of gastric bleeding induced in rats by aspirin plus clopidogrel under stimulation of acid secretion. Prophylactic effects of antiulcer drugs.
Topics: Animals; Anti-Ulcer Agents; Aspirin; Clopidogrel; Drug Interactions; Famotidine; Gastric Acid; Gastr | 2012 |
[Effect of various antisecretory drugs on morphological changes in rat gastric mucosa in experimental stomach ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Epithelium; Famotidine; Gastric | 2002 |
[Pharmacotherapy of non-associated with Helicobacter pylori ulcer].
Topics: Adult; Antacids; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Helicobacter pylori; Humans; | 2002 |
Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
Topics: Adult; Anti-Ulcer Agents; Area Under Curve; Cimetidine; Duodenal Ulcer; Famotidine; Female; Gastrins | 2002 |
Lafutidine, a novel histamine H2-receptor antagonist, increases serum calcitonin gene-related peptide in rats after water immersion-restraint stress.
Topics: Acetamides; Animals; Calcitonin Gene-Related Peptide; Famotidine; Histamine H2 Antagonists; Immersio | 2003 |
Protective role of vanilloid receptor type 1 in HCl-induced gastric mucosal lesions in rats.
Topics: Acetamides; Animals; Anti-Ulcer Agents; Capsaicin; Catechols; Diterpenes; Famotidine; Fatty Alcohols | 2004 |
Antiinflammatory and antiulcer activities of phytic acid in rats.
Topics: Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Cold Temperature; Ethanol; Famotidine; Gastric | 2004 |
Omeprazole is more effective than famotidine for preventing acute gastritis in rats.
Topics: Animals; Anti-Ulcer Agents; Cell Count; Famotidine; Gastric Acid; Gastric Mucosa; Gastritis; Hydroge | 2004 |
Unusual erythemas with eosinophilia, caused by H2-blocker famotidine in a male patient with glioblastoma.
Topics: Aged; Biopsy, Needle; Brain Neoplasms; Eosinophilia; Erythema; Famotidine; Follow-Up Studies; Gliobl | 2004 |
Anisakis in a biopsy specimen from the edge of a gastric ulcer: report of a case.
Topics: Animals; Anisakiasis; Anti-Ulcer Agents; Biopsy; Endoscopy, Digestive System; Famotidine; Female; Hu | 2004 |
Effects of Momordica charantia L. (Cucurbitaceae) on indomethacin-induced ulcer model in rats.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dietary Fats, Unsaturated; D | 2005 |
Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Acetic Acid; Animals; Chlorpheniramine; Chronic Disease; Drug Synergis | 2005 |
Antiulcer and in vitro antioxidant activities of Jasminum grandiflorum L.
Topics: Animals; Anti-Ulcer Agents; Antioxidants; Disease Models, Animal; Dose-Response Relationship, Drug; | 2007 |
Inhibition of neutrophil activation by lafutidine, an H2-receptor antagonist, through enhancement of sensory neuron activation contributes to the reduction of stress-induced gastric mucosal injury in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Acetamides; Animals; Anti-Ulcer Agents; Arachidonic Acids; Calcitonin | 2007 |
[Gastroprotective effects of histamine H2-receptor blockers in Helicobacter-like gastric mucosa lesions].
Topics: Animals; Disease Models, Animal; Famotidine; Female; Gastric Mucosa; Helicobacter Infections; Histam | 2005 |
Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer.
Topics: Acute Disease; Animals; Anti-Ulcer Agents; Cytokines; Disease Models, Animal; Ethanol; Famotidine; G | 2007 |
Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Animals; Anti-Ulcer Agents; Antioxidants; Catalas | 2007 |
Effect of a new potent H2-blocker, 3-[[[2-(diaminomethylene)amino]-4-thiazolyl]methyl]thio]-N2-sulfamoyl propionamidine (YM-11170), on gastric secretion, ulcer formation and weight of male accessory sex organs in rats.
Topics: Androgen Antagonists; Animals; Aspirin; Castration; Cimetidine; Famotidine; Gastric Juice; Gastric M | 1982 |
[Effects of protective agents on ulcer formation].
Topics: Adult; Animals; Cimetidine; Dogs; Duodenal Ulcer; Famotidine; Gastric Juice; Gastric Mucosa; Humans; | 1984 |
Sulpiride specifically attenuates psychological stress-induced gastric lesions in rodents.
Topics: Animals; Anti-Ulcer Agents; Famotidine; Gastric Acid; Indomethacin; Male; Mice; Mice, Inbred ICR; Py | 1995 |
Effects of FK506, an immunosuppressive agent, on genesis of water-immersion stress-induced gastric lesions in rats.
Topics: Animals; Famotidine; Gastric Mucosa; Immersion; Leukotrienes; Male; Omeprazole; Peroxidase; Polyethy | 1994 |
Mucosal regeneration of gastric ulcer confirmed by electronic endoscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Electronics, Medical; Famot | 1995 |
[Therapeutic effect of IGN-2098, a new antiulcer drug (H2-antagonist), in the ulcer diminishing period against acetic acid-induced gastric ulcer in rats].
Topics: Acetates; Acetic Acid; Animals; Anti-Ulcer Agents; Famotidine; Histamine H2 Antagonists; Male; Piper | 1995 |
Different mechanisms mediated by dopamine D1 and D2 receptors are involved etiologically in activity-stress gastric lesion of the rat.
Topics: Animals; Atropine; Cerebral Cortex; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Famotidi | 1995 |
Endoscopic ultrasonographic evaluation of gastric ulcer healing on treatment with proton pump inhibitors versus H2-receptor antagonists.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Gastros | 1994 |
Hyperplastic polyps following treatment of acute gastric ulcers.
Topics: Esophageal and Gastric Varices; Famotidine; Female; Humans; Hyperplasia; Middle Aged; Omeprazole; Po | 1994 |
YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.
Topics: Animals; Anti-Ulcer Agents; Benzodiazepines; Duodenal Ulcer; Epirizole; Ethanol; Famotidine; Gastric | 1994 |
Pharmacodynamics of famotidine in gastric ulcer.
Topics: Circadian Rhythm; Drug Administration Schedule; Famotidine; Gastric Acid; Humans; Stomach Ulcer | 1994 |
Inhibition of phase III activity by acid in canine stomach.
Topics: Animals; Disease Models, Animal; Dogs; Duodenal Ulcer; Electrodes; Electrophysiology; Famotidine; Fe | 1994 |
Healing-promoting action of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl]urea with dual action on chronic gastric and duodenal ulcers induced by acetic acid in rats.
Topics: Acetates; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Duodenal Ulcer; Famotidine; | 1993 |
Cytomegalovirus-associated gastric ulcerations in a normal host.
Topics: Adult; Cytomegalovirus Infections; Famotidine; Humans; Inclusion Bodies, Viral; Male; Stomach; Stoma | 1994 |
The relationship between endoscopic findings of gastric ulcer scar and ulcer relapse.
Topics: Adult; Aged; Aged, 80 and over; Famotidine; Female; Gastric Mucosa; Gastroscopy; Humans; Male; Middl | 1993 |
Acid inhibition and gastric ulcer.
Topics: Circadian Rhythm; Famotidine; Gastric Acid; Humans; Stomach Ulcer | 1993 |
Efficacy of famotidine for omeprazole-refractory gastric ulcer.
Topics: Adult; Famotidine; Humans; Male; Omeprazole; Stomach Ulcer | 1993 |
New drug to prevent NSAID-related ulcers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulce | 1996 |
Is the incidence of hemorrhagic stress ulceration in surgical critically ill patients affected by modern antacid prophylaxis?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Ulcer Agents; Cimetidine; Critical Care; | 1996 |
Famotidine to prevent peptic ulcer caused by NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Famotidine; Histamine H2 Antagonists; Hu | 1996 |
[Ulfamid in the combined therapy of gastric and duodenal peptic ulcer].
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Combined Modality Therapy; Drug Evaluation; Drug Therap | 1997 |
[Conservative treatment of ulcer hemorrhage with histamine H2 antagonists].
Topics: Adolescent; Adult; Duodenal Ulcer; Endoscopy, Digestive System; Famotidine; Follow-Up Studies; Hista | 1997 |
Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 1997 |
Bone mineral density in patients taking H2-receptor antagonist.
Topics: Adult; Aged; Bone Density; Case-Control Studies; Cimetidine; Duodenal Ulcer; Famotidine; Female; His | 1998 |
[Effect of lafutidine, a novel antiulcer agent, on healing and relapse of acetic acid-induced gastric ulcer in rats].
Topics: Acetamides; Acetic Acid; Animals; Anti-Ulcer Agents; Cimetidine; Dose-Response Relationship, Drug; F | 1998 |
Omeprazole, nitrendipine, famotidine and stress-induced ulcers.
Topics: Animals; Anti-Ulcer Agents; Calcium Channel Blockers; Famotidine; Gastric Mucosa; Histamine H2 Antag | 1997 |
[Famotidine (quamatel) for treatment of ulcer disease].
Topics: Adolescent; Adult; Duodenal Ulcer; Endoscopy, Digestive System; Famotidine; Follow-Up Studies; Hista | 1999 |
[Influence of T-593 on the recurrence and relapse of cryocautery-induced gastric ulcer in rats: sequential observation with an endoscope and histological evaluation].
Topics: Animals; Anti-Ulcer Agents; Cautery; Cryosurgery; Endoscopy; Famotidine; Guanidines; Histamine H2 An | 1998 |
Role of endogenous serotonin and histamine in the pathogenesis of gastric mucosal lesions in unanaesthetised rats with a single treatment of compound 48/80, a mast cell degranulator.
Topics: Adrenergic Uptake Inhibitors; Amitriptyline; Animals; Cell Degranulation; Cimetidine; Cyproheptadine | 1999 |
Antisecretory and ulcer healing effects of S-0509, a novel CCK-B/gastrin receptor antagonist, in rats.
Topics: Animals; Benzophenones; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans; Male; Phenylurea | 1999 |
[Histological study on healing of cryocautery-induced rat gastric ulcer treated with T-593].
Topics: Administration, Oral; Animals; Anti-Ulcer Agents; Cautery; Famotidine; Gastric Mucosa; Guanidines; H | 1999 |
Antiulcer effect of lafutidine on indomethacin-induced gastric antral ulcers in refed rats.
Topics: 16,16-Dimethylprostaglandin E2; Acetamides; Administration, Oral; Animals; Anti-Ulcer Agents; Capsai | 1999 |
Effect of naproxen on the hamster gastric antrum: ulceration, adaptation and efficacy of anti-ulcer drugs.
Topics: Adaptation, Physiological; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cell | 1999 |
A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cel | 2000 |
[Famotidin (quamatel) in the treatment of gastroduodenal ulcer].
Topics: Adult; Drug Administration Routes; Duodenal Ulcer; Endoscopy, Digestive System; Famotidine; Female; | 2000 |
[Quamatel application in three-drug eradication therapy of duodenal ulcer and gastroduodenal ulcerations associated with helicobacter pylori infection].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Fa | 2000 |
Effect of FRG-8813, a new-type histamine H(2)-receptor antagonist, on the recurrence of gastric ulcer after healing by drug treatment in rats.
Topics: Acetamides; Animals; Disease Models, Animal; Endoscopy, Gastrointestinal; Famotidine; Gastric Acidit | 2000 |
Effect of dimethylglycine on gastric ulcers in rats.
Topics: Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Famotidine; Gastric Juice; Glutathione | 2000 |
Protective effect of famotidine, omeprazole, and melatonin against acetylsalicylic acid-induced gastric damage in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antioxidants; Aspirin; Disease | 2001 |
[Experience in clinical use of quamatel in upper gastrointestinal hemorrhage].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Duodenal Ulcer; Famotidine; Female; Gastroin | 2001 |
Delirium following a switch from cimetidine to famotidine.
Topics: Aged; Anti-Ulcer Agents; Cimetidine; Delirium; Famotidine; Female; Humans; Stomach Ulcer | 2001 |
Effects of vanilloid receptor agonists and antagonists on gastric antral ulcers in rats.
Topics: Acetamides; Animals; Anti-Ulcer Agents; Capsaicin; Cations; Ditiocarb; Famotidine; Ion Channels; Mal | 2001 |
Antiulcerogenic effect of Hippophae rhamnoides L.
Topics: Animals; Anti-Ulcer Agents; Disease Models, Animal; Famotidine; Fruit; Indomethacin; Male; Misoprost | 2001 |
[H2 blockers in the treatment of bleeding gastroduodenal ulcers].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Duodenoscopy; Famotidine; Female; Gastro | 2001 |
[Treatment of NSAIDs induced ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
[The gastric mucigenous function in the treatment of patients with ulcer with various antisecretory preparations].
Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors; Famotidine; Female; Gastric Acidity Det | 2002 |
Acidic fibroblast growth factor accelerates the healing of acetic-acid-induced gastric ulcers in rats.
Topics: Acetates; Acetic Acid; Aluminum Hydroxide; Animals; Antacids; Drug Combinations; Famotidine; Female; | 1992 |
[Famotidine in the treatment of stomach ulcer].
Topics: Adult; Aged; Biopsy; Drug Tolerance; Famotidine; Female; Gastroscopy; Humans; Male; Middle Aged; Pai | 1992 |
Effects of histamine H2-receptor antagonists and a proton pump inhibitor on the mucosal hydroxyproline content of ethanol-HCl-induced gastric lesions in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Benz | 1992 |
Possible involvement of hyperinsulinemia and adrenergic activation in the pathogenesis of indomethacin-induced antral ulcers in nonfasted hamsters and refed rats.
Topics: Animals; Atropine; Cricetinae; Famotidine; Fasting; Indomethacin; Insulin; Male; Mesocricetus; Prazo | 1992 |
Identical 24-hour intragastric pH response to low continuous infusion doses of famotidine in active gastric ulcer patients.
Topics: Adult; Age Factors; Aged; Famotidine; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Infu | 1992 |
Cell proliferation kinetics in the marginal mucosa of gastric ulcer evaluated by immunostaining of DNA polymerase alpha.
Topics: Adult; Aged; Antibodies, Monoclonal; Cell Division; Cimetidine; DNA Polymerase II; Famotidine; Femal | 1991 |
Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Esoph | 1991 |
[Effects of IT-066, a new histamine H2-receptor antagonist, on gastric acid secretion and experimental gastric ulcers in rats and dogs].
Topics: Acetates; Animals; Anti-Ulcer Agents; Carbachol; Depression, Chemical; Dogs; Famotidine; Female; Gas | 1990 |
Effects of FRG-8701 on gastric acid secretion, gastric mucosal lesions by necrotizing agents and experimental gastric or duodenal ulcer in rats.
Topics: Acetamides; Animals; Cimetidine; Duodenal Ulcer; Famotidine; Gastric Acid; Gastric Mucosa; Guinea Pi | 1990 |
Studies on the mechanism for the gastric mucosal protection by famotidine in rats.
Topics: Animals; Anti-Ulcer Agents; Cimetidine; Famotidine; Gastric Mucosa; Male; Pirenzepine; Rats; Rats, I | 1991 |
Effect of an endogenous satiety substance, 2-buten-4-olide, on gastric acid secretion and experimental ulceration in rats.
Topics: 4-Butyrolactone; Animals; Cimetidine; Cysteamine; Deoxyglucose; Duodenal Ulcer; Famotidine; Furans; | 1990 |
The pathophysiologic role of nocturnal acid secretion in gastric ulcers.
Topics: Circadian Rhythm; Famotidine; Gastric Acid; Humans; Stomach Ulcer | 1990 |
[Mechanism of prevention of stress ulcer by vagotomy and famotidine: viewed from the transmucosal potential difference and histamine staining by a fluorescence histochemical method].
Topics: Animals; Famotidine; Gastric Mucosa; Histamine; Male; Membrane Potentials; Rats; Rats, Inbred Strain | 1986 |
Characterization of metalloproteinases in rat gastric tissues with acetic acid-induced ulcers.
Topics: Acetates; Acetic Acid; Animals; Enzyme Precursors; Famotidine; Gastric Mucosa; Gelatin; Male; Metall | 1989 |
[Famotidine. Pharmacologic and clinical profile of the new histamine H2 receptor antagonist].
Topics: Animals; Duodenal Ulcer; Famotidine; Guinea Pigs; Histamine H2 Antagonists; Humans; Kinetics; Stomac | 1986 |
Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
Topics: Duodenal Ulcer; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans; Recurrence; Stomach Ulce | 1987 |
Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine.
Topics: Animals; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Gastric Emptying; Gastric Mucosa; Hi | 1987 |
Effects of short- and long-term administrations of famotidine and ranitidine on some pituitary, sexual and thyroid hormones.
Topics: Adult; Famotidine; Follicle Stimulating Hormone; Histamine H2 Antagonists; Humans; Luteinizing Hormo | 1987 |
Effect of the H2-blocker famotidine on gastric mucosal prostaglandin levels in water immersion stress in rats.
Topics: Animals; Famotidine; Gastric Mucosa; Histamine H2 Antagonists; Immersion; Male; Phospholipases; Pros | 1988 |
Recurrent parotitis with H2 receptor antagonists in a patient with Sjogren's syndrome.
Topics: Cimetidine; Famotidine; Female; Histamine H2 Antagonists; Humans; Middle Aged; Parotitis; Ranitidine | 1988 |
[Famotidine treatment of patients with gastric and duodenal ulcers. A comparative study with once or twice-a-day administration].
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Evaluation; Duodenal Ulcer; Famotidine; Histamine H2 Antagonist | 1987 |
[Effect of an H+, K+-ATPase inhibitor, omeprazole (OPZ), on gastric acid secretion and gastric or duodenal lesion. Comparison with an H2-receptor antagonist, famotidine (FMD)].
Topics: Animals; Dogs; Duodenitis; Famotidine; Female; Gastric Acid; Histamine H2 Antagonists; Male; Omepraz | 1988 |
Famotidine-associated mental confusion in elderly patients.
Topics: Aged; Cognition Disorders; Confusion; Famotidine; Female; Humans; Male; Stomach Ulcer; Thiazoles | 1988 |
Hemodynamics of the gastric mucosa and gastric ulceration in rats and in patients with gastric ulcer.
Topics: Animals; Blood Volume; Famotidine; Gastric Mucosa; Hemodynamics; Histamine; Humans; Microcirculation | 1986 |